Cynda(SH:603086) Xin Lang Cai Jing·2026-01-26 08:23Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 135 million to 155 million yuan for the year 2025, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The anticipated net profit represents a significant improvement compared to the previous year, indicating a successful recovery [1] - The sales price of the company's main product, Acetochlor, has significantly increased compared to the same period last year, contributing to the overall improvement in gross margin [1] Group 2: Product Development - The successful launch and sales of the newly developed product series, Pyrazole Quinclorac, have further boosted the gross margin of domestic formulation products [1] Group 3: Operational Efficiency - The company is continuously advancing operational reforms, implementing a gross profit distribution plan, and strengthening cost and expense control, leading to improved overall operational efficiency [1]